May 26, 2023
Japan’s health ministry approved a batch of drugs for label expansion on May 25 including Alexion Pharmaceuticals’ anti-C5 antibody Ultomiris (ravulizumab) for an additional indication of neuromyelitis optica spectrum disorder (NMOSD). The Ministry of Health, Labor and Welfare (MHLW) gave...read more